Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 2 examiners • 0 of 4 (0%) have an AI response strategy ready
Rem Brands Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 4 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows a level of diversification in the company's active prosecution. The presence of 2 art units suggests that the company's intellectual property may span different sub-specialties within the broader pharmaceutical field.
The busiest examiner for the portfolio is HIRT, ERIN E, who is responsible for 3 busiest examiner pending office actions. This means 3 of the company's 4 pending actions are concentrated with a single individual. Practitioners should note that the prosecution success in the Biotechnology & Pharmaceuticals area for Rem Brands Inc. is influenced by the decisions of this specific examiner. With the pending workload assigned to HIRT, ERIN E, this examiner's approach to patentability and prior art will be a factor in the portfolio's near-term development.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRT, ERIN E | 3 | 40.3% | +23.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17971209 | ANIMAL LITTER AND BEDDING | HIRT, ERIN E | 21d |
| 17971233 | ANTIMICROBIAL BEDDING PRODUCT FOR PETS AND ANIMALS | HIRT, ERIN E | — |
| 17877361 | ANTI-MICROBIAL SULFONAMIDE PHARMACEUTICAL COMPOSITIONS FOR EXTERNAL USE | SZNAIDMAN, MARCOS L | — |
| 16990471 | HALO ACTIVE AROMATIC SULFONAMIDE ANTIMICROBIAL AND ODOR CONTROL COATINGS | HIRT, ERIN E | — |
| Art Unit | Apps |
|---|---|
| 1616 | 3 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17971233 | ANTIMICROBIAL BEDDING PRODUCT FOR PETS AND ANIMALS | HIRT, ERIN E | 1616 | §103DP | Final Rejection | — | Pending | Oct 21, 2022 |
| 17971209 | ANIMAL LITTER AND BEDDING | HIRT, ERIN E | 1616 | §103 | Final Rejection | 21d | Pending | Oct 21, 2022 |
| 17877361 | ANTI-MICROBIAL SULFONAMIDE PHARMACEUTICAL COMPOSITIONS FOR EXTERNAL USE | SZNAIDMAN, MARCOS L | 1628 | §102DP | Final Rejection | — | Pending | Jul 29, 2022 |
| 16990471 | HALO ACTIVE AROMATIC SULFONAMIDE ANTIMICROBIAL AND ODOR CONTROL COATINGS | HIRT, ERIN E | 1616 | §103§112DP | Final Rejection | — | Pending | Aug 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial